Dengue vaccine safety signal: Immune enhancement, waning immunity, or chance occurrence? (Q38772532)

6 September 2017

Dengue vaccine safety signal: Immune enhancement, waning immunity, or chance occurrence? (English)

1 reference

6 September 2017

0 references

1 reference

1

Bradford D Gessner

1 reference

6 September 2017

2

Neal Halsey

1 reference

PubMed ID

28528764

6 September 2017

language of work or name

English

0 references

publication date

18 May 2017

1 reference

6 September 2017

1 reference

6 September 2017

35

1 reference

6 September 2017

27

1 reference

6 September 2017

3452-3456

1 reference

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

6 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.003

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.003

Protective and immunological behavior of chimeric yellow fever dengue vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.003

Answer to the review from Halstead and Russell "Protective and immunological behavior of chimeric yellow fever dengue vaccine" (DOI 10.1016/j.vaccine.2016.02.004).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.003

Human immune responses to dengue virus infection: lessons learned from prospective cohort studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.003

A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.003

Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.003

Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.003

Population Perspectives and World Health Organization Recommendations for CYD-TDV Dengue Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.003

Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.003

Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.003

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.05.003

10.1016/J.VACCINE.2017.05.003

7 January 2021

Identifiers

DOI

1 reference

6 September 2017

1 reference

PubMed ID

28528764